OA12178A - Substituted arylpyrazines. - Google Patents

Substituted arylpyrazines. Download PDF

Info

Publication number
OA12178A
OA12178A OA1200200251A OA1200200251A OA12178A OA 12178 A OA12178 A OA 12178A OA 1200200251 A OA1200200251 A OA 1200200251A OA 1200200251 A OA1200200251 A OA 1200200251A OA 12178 A OA12178 A OA 12178A
Authority
OA
OAPI
Prior art keywords
compound according
alkyl
named
amine
phenyl
Prior art date
Application number
OA1200200251A
Other languages
English (en)
Inventor
Stephane De Lombaert
Dario Doller
Ping Ge
Kevin J Hodgetts
Raymond F Horvath
Taeyoung Yoon
Cunyu Zhang
Original Assignee
Neurogen Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurogen Corp filed Critical Neurogen Corp
Publication of OA12178A publication Critical patent/OA12178A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/12—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/18—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Photoreceptors In Electrophotography (AREA)
  • Pyridine Compounds (AREA)
OA1200200251A 2000-02-16 2001-02-16 Substituted arylpyrazines. OA12178A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18293400P 2000-02-16 2000-02-16
US20645500P 2000-05-22 2000-05-22

Publications (1)

Publication Number Publication Date
OA12178A true OA12178A (en) 2003-12-24

Family

ID=26878562

Family Applications (1)

Application Number Title Priority Date Filing Date
OA1200200251A OA12178A (en) 2000-02-16 2001-02-16 Substituted arylpyrazines.

Country Status (34)

Country Link
US (3) US6995161B2 (xx)
EP (1) EP1255740B1 (xx)
JP (1) JP2004500383A (xx)
KR (2) KR20030031886A (xx)
CN (1) CN1231473C (xx)
AP (1) AP2002002620A0 (xx)
AT (1) ATE307121T1 (xx)
AU (1) AU783915B2 (xx)
BG (2) BG106968A (xx)
BR (1) BR0108363A (xx)
CA (2) CA2651825A1 (xx)
CR (1) CR6735A (xx)
CZ (1) CZ20022739A3 (xx)
DE (1) DE60114153T2 (xx)
DK (1) DK1255740T3 (xx)
DZ (1) DZ3293A1 (xx)
EA (1) EA006938B1 (xx)
EE (1) EE200200453A (xx)
ES (1) ES2247070T3 (xx)
HK (1) HK1051191A1 (xx)
HR (1) HRP20020747A2 (xx)
HU (1) HUP0301573A3 (xx)
IL (1) IL151020A0 (xx)
IS (1) IS2192B (xx)
MA (1) MA26874A1 (xx)
MX (1) MXPA02007868A (xx)
NO (1) NO324473B1 (xx)
NZ (1) NZ520484A (xx)
OA (1) OA12178A (xx)
PL (1) PL365238A1 (xx)
SK (1) SK11542002A3 (xx)
TW (1) TWI232215B (xx)
WO (1) WO2001060806A2 (xx)
YU (1) YU61002A (xx)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002024681A2 (en) 2000-09-20 2002-03-28 Ortho-Mcneil Pharmaceutical, Inc. Pyrazine derivatives as modulators of tyrosine kinases
BR0209920A (pt) 2001-05-22 2004-03-30 Neurogen Corp Composto ou sal farmaceuticamente aceitável do mesmo, métodos de tratar ansiedade, depressão ou estresse e sìndrome do intestino irritável ou doença de crohn, de detectar receptores de crf1 em uma primeira amostra biológica, de demonstrar a presença ou ausência de receptores de crf1 em uma amostra biológica e de inibir a ligação de crf a um receptor de crf1, composição farmacêutica, e, embalagem
AP2003002924A0 (en) * 2001-06-12 2003-12-31 Neurogen Corp 2,5-diarylpyrazines, 2,5 - diarylpyridines and 2,5 - diarylpyrimidines as CRF1 receptor modulators
SE0102438D0 (sv) * 2001-07-05 2001-07-05 Astrazeneca Ab New compounds
SE0102439D0 (sv) * 2001-07-05 2001-07-05 Astrazeneca Ab New compounds
US6852737B2 (en) * 2001-08-06 2005-02-08 Recordati Ireland Limited Crude and crystalline forms of lercanidipine hydrochloride
ITMI20011726A1 (it) 2001-08-06 2003-02-06 Recordati Ind Chimica E Farma Forme polimorfe della lercanidipina cloridrato
US6992087B2 (en) 2001-11-21 2006-01-31 Pfizer Inc Substituted aryl 1,4-pyrazine derivatives
MXPA04004714A (es) * 2001-11-21 2004-08-19 Upjohn Co Derivados de aril 1,4-pirazina sustituidos.
MXPA04008384A (es) * 2002-04-26 2004-11-26 Upjohn Co Derivados de pirazina sustituidos.
WO2004000318A2 (en) 2002-06-21 2003-12-31 Cellular Genomics, Inc. Certain amino-substituted monocycles as kinase modulators
CA2496197A1 (en) 2002-08-20 2004-03-04 Neurogen Corporation 5-substituted-2-arylpyrazines as modulators of crf receptors
EP1539736A1 (en) * 2002-09-12 2005-06-15 Pharmacia & Upjohn Company LLC Substituted 1,4-pyrazine derivatives
EP1565454A1 (en) * 2002-11-21 2005-08-24 Pharmacia & Upjohn Company LLC Pyrazine compounds as crf modulators
SE0203753D0 (sv) * 2002-12-17 2002-12-17 Astrazeneca Ab New compounds
SE0203754D0 (sv) * 2002-12-17 2002-12-17 Astrazeneca Ab New compounds
DK1603570T5 (da) 2003-02-26 2013-12-09 Sugen Inc Aminoheteroarylforbindelser som proteinkinaseinhibitorer
JP2006525993A (ja) 2003-05-09 2006-11-16 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー Ｃｒｆ１受容体拮抗剤である化合物
CA2524352A1 (en) 2003-05-09 2004-11-18 Pharmacia & Upjohn Company Llc Substituted pyrimidine derivatives
US7595316B2 (en) * 2003-06-27 2009-09-29 Banyu Pharmaceutical Co., Ltd. Heteroaryloxy nitrogenous saturated heterocyclic derivative
BRPI0415863A (pt) * 2003-10-27 2007-01-09 Astellas Pharma Inc derivados pirazina e seus usos farmacêuticos
US20060211710A1 (en) * 2005-03-17 2006-09-21 Pfizer Inc Substituted aryl 1,4-pyrazine derivatives
AR053712A1 (es) * 2005-04-18 2007-05-16 Neurogen Corp Heteroarilos sustituidos, antagonistas de cb1 (receptor 1 canabinoide)
PL1959955T3 (pl) * 2005-12-05 2011-04-29 Pfizer Prod Inc Sposób traktowania nieprawidłowego wzrostu komórek
AU2006323025B2 (en) * 2005-12-05 2012-07-05 Pfizer Products Inc. Polymorphs of a c-Met/HGFR inhibitor
SG157264A1 (en) * 2008-06-02 2009-12-29 Inzign Pte Ltd A golf tee and method of producing a golf tee
US7932256B2 (en) * 2008-07-31 2011-04-26 Bristol-Myers Squibb Company (S)-4-(1-cyclopropyl-2-methoxyethyl)-6-(6-(difluoromethoxy)-2,5-dimethylpyridin-3-ylamino)-5-oxo-4,5-dihydropyrazine-2-carbonitrile: a pyrazinone modulator of corticotropin-releasing factor receptor activity
MX369857B (es) 2014-02-14 2019-11-25 Takeda Pharmaceuticals Co Pirazinas moduladoras de receptor 6 acoplado a la proteina g (gpr6).
AU2015367977B9 (en) 2014-12-24 2020-02-06 Lg Chem, Ltd Biaryl derivative as GPR120 agonist
JP6916279B2 (ja) 2016-07-12 2021-08-11 レヴォリューション・メディスンズ，インコーポレイテッド アロステリックｓｈｐ２阻害剤としての２，５−二置換３−メチルピラジンおよび２，５，６−三置換３−メチルピラジン
WO2018136265A1 (en) 2017-01-23 2018-07-26 Revolution Medicines, Inc. Bicyclic compounds as allosteric shp2 inhibitors
EP4230623A3 (en) 2017-01-23 2023-10-11 Revolution Medicines, Inc. Pyridine compounds as allosteric shp2 inhibitors
RU2672470C1 (ru) * 2017-07-10 2018-11-15 Федеральное государственное бюджетное учреждение науки Институт нефтехимии и катализа Российской академии наук Способ получения 2,3,5,6-тетрафенил(бензил)пиразина
CA3078565A1 (en) 2017-10-12 2019-04-18 Revolution Medicines, Inc. Pyridine, pyrazine, and triazine compounds as allosteric shp2 inhibitors
EP3724189B1 (en) 2017-12-15 2023-10-04 Revolution Medicines, Inc. Polycyclic compounds as allosteric shp2 inhibitors
JP2021523933A (ja) * 2018-04-20 2021-09-09 バージニア・テック・インテレクチュアル・プロパティーズ・インコーポレイテッドＶｉｒｇｉｎｉａ Ｔｅｃｈ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｉｅｓ， Ｉｎｃ． ミトコンドリア脱共役剤として有用なイミダゾピリジン
EP3982949A4 (en) * 2019-06-14 2023-10-11 Disarm Therapeutics, Inc. MRSA1 INHIBITORS
GB202006076D0 (en) * 2020-04-24 2020-06-10 Univ Greenwich Interleukin inhibitors

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2425355A1 (de) 1974-05-25 1975-12-04 Basf Ag Verfahren zur herstellung von pyrazinen
EG12387A (en) * 1975-04-21 1978-12-31 Merck & Co Inc Process for preparing of piperazinyl pyrazines
FR2398738A1 (fr) * 1977-06-22 1979-02-23 Lilly Co Eli Preparation de benzoylurees
US4293552A (en) * 1978-02-27 1981-10-06 Eli Lilly And Company Novel 1-(mono-o-substituted benzoyl)-3-(substituted pyrazinyl) ureas
US4211870A (en) * 1979-04-06 1980-07-08 Eli Lilly And Company Preparation of substituted 2-aminopyrazines
JPS59144772A (ja) * 1983-02-08 1984-08-18 Ube Ind Ltd 液晶性ピラジン誘導体およびその製法
JPS625970A (ja) * 1985-03-15 1987-01-12 Terumo Corp ピラジン誘導体およびこれを含有する血小板凝集抑制剤
JPH0739398B2 (ja) * 1986-10-04 1995-05-01 宇部興産株式会社 液晶性ピラジン誘導体
NZ227684A (en) * 1988-01-30 1991-07-26 Merck Sharp & Dohme Pyrazine, pyridazine, and pyrimidine derivatives and pharmaceutical compositions
JPH0348666A (ja) 1989-07-17 1991-03-01 Rasa Kogyo Kk 芳香族ジアミン化合物の製造方法
DE3940477A1 (de) * 1989-12-07 1991-06-13 Bayer Ag Hetaryl-substituierte pyridinylpyrimidin-derivate
GB2272216A (en) * 1992-11-04 1994-05-11 Merck Patent Gmbh Liquid crystalline di-, tri- and tetra-fluorinated phenylpyrazines
WO1995010506A1 (en) 1993-10-12 1995-04-20 The Du Pont Merck Pharmaceutical Company 1n-alkyl-n-arylpyrimidinamines and derivatives thereof
AU7095496A (en) * 1995-09-26 1997-04-17 Nippon Soda Co., Ltd. Pyrazole compounds, process for preparing the same, and agrohorticultural bactericide
WO1998011075A1 (en) 1996-09-16 1998-03-19 Du Pont Pharmaceuticals Company Pyrazinones and triazinones and their derivatives thereof
MA26473A1 (fr) * 1997-03-01 2004-12-20 Glaxo Group Ltd Composes pharmacologiquement actifs.
BE1011077A3 (fr) 1997-03-28 1999-04-06 Univ Catholique Louvain Composition pharmaceutique, cosmetique et/ou alimentaire aux proprietes anti-oxydantes.
CN1231440C (zh) 1998-01-28 2005-12-14 盐野义制药株式会社 新的三环化合物
GB9818881D0 (en) 1998-08-28 1998-10-21 Glaxo Group Ltd Compounds
WO2000045800A2 (en) 1999-02-02 2000-08-10 K.U. Leuven Research & Development Immunosurpressive effects of pteridine derivatives

Also Published As

Publication number Publication date
BR0108363A (pt) 2004-02-10
CA2651825A1 (en) 2001-08-23
WO2001060806A2 (en) 2001-08-23
DK1255740T3 (da) 2006-02-06
AU783915B2 (en) 2005-12-22
WO2001060806A3 (en) 2002-02-07
ATE307121T1 (de) 2005-11-15
IS2192B (is) 2007-01-15
AP2002002620A0 (en) 2002-09-30
US20050215559A1 (en) 2005-09-29
HRP20020747A2 (en) 2004-12-31
EE200200453A (et) 2003-12-15
CR6735A (es) 2003-11-25
HUP0301573A2 (hu) 2003-12-29
EA200200766A1 (ru) 2003-10-30
BG106968A (bg) 2003-04-30
DE60114153T2 (de) 2006-07-06
US6995161B2 (en) 2006-02-07
IS6488A (is) 2002-07-29
EA006938B1 (ru) 2006-06-30
IL151020A0 (en) 2003-02-12
CZ20022739A3 (cs) 2003-02-12
DZ3293A1 (fr) 2001-08-23
JP2004500383A (ja) 2004-01-08
SK11542002A3 (sk) 2003-03-04
CN1231473C (zh) 2005-12-14
TWI232215B (en) 2005-05-11
BG110174A (en) 2009-05-29
US20070225287A1 (en) 2007-09-27
NO324473B1 (no) 2007-10-29
HK1051191A1 (en) 2003-07-25
DE60114153D1 (de) 2006-03-02
KR20030031886A (ko) 2003-04-23
EP1255740B1 (en) 2005-10-19
CN1400970A (zh) 2003-03-05
EP1255740A2 (en) 2002-11-13
MA26874A1 (fr) 2004-12-20
YU61002A (sh) 2005-06-10
CA2398937A1 (en) 2001-08-23
AU3849401A (en) 2001-08-27
NO20023869L (no) 2002-09-11
NZ520484A (en) 2005-03-24
HUP0301573A3 (en) 2004-03-29
ES2247070T3 (es) 2006-03-01
US7202250B2 (en) 2007-04-10
NO20023869D0 (no) 2002-08-15
US20030018035A1 (en) 2003-01-23
PL365238A1 (en) 2004-12-27
KR20080021603A (ko) 2008-03-07
MXPA02007868A (es) 2003-02-10

Similar Documents

Publication Publication Date Title
OA12178A (en) Substituted arylpyrazines.
EP1513821B1 (en) Protein kinase inhibitors
US20050176721A1 (en) 2,5-Diarylpyrazines, 2,5-diarylpyridines and 2,5-diarylprimidines
US20070043056A1 (en) 5-Substituted-2-arylpyrazines
CA2416248A1 (en) 5-substituted 2-aryl-4-pyrimidinones
ZA200409341B (en) Protein kinase inhibitors.
AU4368001A (en) 5-substituted arylpyrimidines
EP1500653A1 (en) Substituted arylpyrazines
ZA200206103B (en) Substituted arylpyrazines.